WaveMan
WaveMan · Company
NVCT · Nuvectis Pharma, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

NVCT Nuvectis Pharma (NVCT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001875558
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
63
13F, latest reported quarter

What the filings say about NVCT

Insiders, 180 days
+$1.2M net bought
2 buyers

Nuvectis Pharma insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Nuvectis Pharma, Inc. insiders bought a net $1.2M of stock across 151 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BENTSUR RON
Chairman & CEO
BUY
2026-07-01 SECtraded 2026-06-30
12,500
$250.0K
-5.5%
Context
  • 76 earlier Form 4 trades (code P or S) here by this insider (76 buys), the last on Nov 5, 2025.
  • -19.8% median (-10.4% mean) 90-day return after 30 previous buys.
  • The trade is 0.3% of the 3,688,424 shares held after it.
  • 1 other insider bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO BENTSUR RON bought about $250.0K of NVCT on Jun 30, 2026; 1 other insider bought within 30 days and 63 funds added in the latest 13F quarter.
Mosseri Marlio Charles
BUY
2026-07-01 SECtraded 2026-06-30
50,000
$916.0K
-5.5%
Context
  • 42 earlier Form 4 trades (code P or S) here by this insider (42 buys), the last on Oct 27, 2025.
  • -27.0% median (-12.8% mean) 90-day return after 30 previous buys.
  • The trade is 1.6% of the 3,186,576 shares held after it.
  • 1 other insider bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Mosseri Marlio Charles bought about $916.0K of NVCT on Jun 30, 2026, the largest insider purchase at the company since 2025; 1 other insider bought within 30 days and 63 funds added in the latest 13F quarter.
BENTSUR RON
Chairman & CEO
BUY
2025-11-06 SECtraded 2025-11-05
5,000
$28.6K
+201.1%
Context
  • 75 earlier Form 4 trades (code P or S) here by this insider (75 buys), the last on Dec 24, 2024.
  • -19.8% median (-9.8% mean) 90-day return after 30 previous buys.
  • The trade is 0.1% of the 3,525,924 shares held after it.
  • 3 other insiders bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman & CEO BENTSUR RON bought about $28.6K of NVCT on Nov 5, 2025; 3 other insiders bought within 30 days and 63 funds added in the latest 13F quarter.
Sanchez Juan
Director
BUY
2025-11-06 SECtraded 2025-11-05
13,000
$75.3K
+201.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 16.6% of the 78,150 shares held after it.
  • 3 other insiders bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sanchez Juan bought about $75.3K of NVCT on Nov 5, 2025; 3 other insiders bought within 30 days and 63 funds added in the latest 13F quarter.
Kaplan Matthew L.
Director
BUY
2025-11-06 SECtraded 2025-11-05
11,000
$64.2K
+201.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 12, 2022.
  • The trade is 8.8% of the 124,760 shares held after it.
  • 3 other insiders bought within 30 days.
  • 63 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kaplan Matthew L. bought about $64.2K of NVCT on Nov 5, 2025; 3 other insiders bought within 30 days and 63 funds added in the latest 13F quarter.
151 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 146 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$1.2M over 180 days
+$1.2M of it by a 10%+ holder
more than 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
63 funds bought in last quarter
more than 52% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.9% of the float short (float per yahoo 2026-10-26) · 10.3 days to cover · settled 2026-09-30
more than 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NVCT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+207.7%12M
-6%+121%+248%+375%2025-102025-122026-022026-042026-062026-082026-10 2026-06-30 · Mosseri Marlio Charles bought $916.0K2025-10-27 · Mosseri Marlio Charles bought $457.4K2025-10-23 · Mosseri Marlio Charles bought $284.2K2026-06-30 · BENTSUR RON bought $250.0K2025-10-24 · Mosseri Marlio Charles bought $215.5K2025-11-05 · Sanchez Juan bought $75.3K2025-11-05 · Kaplan Matthew L. bought $64.2K2025-11-05 · BENTSUR RON bought $28.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NVCT: institutional holders (13F)

13F holdings, latest reported quarter
TANG CAPITAL MANAGEMENT LLC
1,550,000 sh
$28.5M
BlackRock, Inc.
1,001,285 sh
$18.4M
PERCEPTIVE ADVISORS LLC
1,000,000 sh
$18.4M
Soleus Capital Management, L.P.
1,000,000 sh
$18.4M
VANGUARD CAPITAL MANAGEMENT LLC
872,482 sh
$16.0M

Congress trades in NVCT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NVCT planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

NVCT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
1290 VT Micro Cap Portfolio
$69.6K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$2.9M position · as of 2026-06-30
0.0%
Fidelity Small Cap Growth Index Fund
$294.6K position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$27.9K position · as of 2026-06-30
0.0%
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF
$156.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 1
3 active
What changed recently
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
2026-10-01 · Recruiting → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.2M bought by insiders over 180 days, 63 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NVCT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-214.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-112.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-222.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$27.6M-$19.8M-$22.9M-$19.2M
Net income-$26.4M-$19.0M-$22.3M-$19.1M
EPS (diluted)-1.32-1.11-1.43-1.51
Operating cash flow-$16.0M-$12.2M-$16.0M-$13.6M
Cash$31.6M$18.5M$19.1M$20.0M
SEC XBRL, fiscal years, as known on 2026-10-28

NVCT Stock Sonar score 4/7 axes

Find similar shapesCompare

NVCT ranks highest on insider conviction (85th percentile) and institutional and government (52nd), and lowest on profitability (15th), among Pharma & Biotech peers.

Profitability
15
Inputs
  • Return on equity-214.6% · 15 pct, sector of 545
  • Return on assets-112.8% · 22 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-222.5% · 9 pct, sector of 576
Insider conviction
85
Inputs
  • Net Form 4 buying (codes P and S), 180d$1.2M · 89 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
52
Inputs
  • Funds adding, latest quarter63 · 52 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
33
Inputs
  • Short interest, % of float+11.9% · 33 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NVCT filings, in plain words

Are Nuvectis Pharma insiders buying or selling NVCT?

In the 180 days to 2026-10-28, Nuvectis Pharma insiders were net buyers, a net $1.2M across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Nuvectis Pharma insiders were net buyers of NVCT, a net $1.2M across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $1.2M, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies